A panel of the US Food and Drug and Administration voted narrowly not to recommend the approval of a first-in-class therapy developed by Bristol-Myers Squibb Company and Astra-Zeneca Plc for diabetes. ---Subscribe to MedNous to access this article--- Regulation & Policy Company News
